Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Patient enrollment begins in U.S. phase III trial of beraprost

Feb. 2, 2000

Studies at DuPont suggest clinical utility of SF-303 and SK-549 as novel antithrombotics

Jan. 28, 2000

EPISTENT diabetic subgroup results: abciximab + stenting associated with better outcome

Jan. 26, 2000

DuPont scientists prepare new antiplatelet fibrinogen antagonists

Jan. 26, 2000

RPR-120844: pharmacodynamic and antithrombotic profile of a new factor Xa inhibitor

Jan. 21, 2000

Searle designs double prodrugs of gpIIb/IIIa antagonists

Jan. 20, 2000

Antiplatelet agent OPC-29030 appears to act by inhibiting 12-lipoxygenase translocation

Jan. 19, 2000

Selective factor Xa inhibitor assessed in experimental model of tumor-induced DIC

Jan. 13, 2000

Phase III data reported for rhATIII

Jan. 12, 2000

New thrombin inhibitors presented by Merck & Co. research group

Jan. 6, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...